Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes (Q38058568)

27 August 2017

title

Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes (English)

1 reference

27 August 2017

1 reference

1 reference

Rosemarie Lajara

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

9 November 2012

1 reference

Expert Opinion on Pharmacotherapy

27 August 2017

published in

1 reference

27 August 2017

volume

13

1 reference

27 August 2017

issue

18

1 reference

27 August 2017

page(s)

2663-2671

1 reference

Biology of incretins: GLP-1 and GIP

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Molecular mechanisms underlying nutrient detection by incretin-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjec

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Development of the American Association of Diabetes Educators' Diabetes Self-management Assessment Report Tool.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Mild hypoglycemia is independently associated with increased mortality in the critically ill.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Vascular disease and diabetes: is hypoglycaemia an aggravating factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Serious cardiovascular outcomes in diabetes: the role of hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Severe hypoglycemia and risks of vascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.741591

10.1517/14656566.2012.741591

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference